"Success is defined many times in life as doing something very well and sometimes only one thing. That can be true in business as well, and we have chosen treatment for patients with cancer as a singular focus by which to measure success. In doing so we have the opportunity to do the right thing very well for the benefit of medicine, patients, physicians, payers and the healthcare system overall. Having seen both family members and friends die from cancer in recent years, I can think of no better way to spend my day than helping others who will be faced with similar circumstances in the future.”
Brad Cole has been influential in steering Genomic Health through its initial public offering in 2005, delivering the company’s first full year of profit in 2010, and expanding the business oversees in an effort to reach cancer patients around the world. Brad has held the title of Chief Financial Officer since 2004. He served as both Chief Operating Officer and Chief Financial Officer from 2009 to 2018. Before joining Genomic Health, Brad served in various positions at Guidant Corporation, a designer and developer of cardiovascular medical products. At Guidant, Brad was Vice President, Finance and Business Development, for the Endovascular Solutions Group from 2001 until 2004. Prior to that, he served as Vice President and General Manager of the Vascular Surgery Business Unit of Guidant. Brad was Vice President, Finance, and Chief Financial Officer of Endovascular Technologies, Inc., a publicly traded medical device company acquired by Guidant Corporation in 1997. Previously, Brad was Vice President and Chief Financial Officer of Applied Biosystems, a publicly traded life sciences company. In 2017, Brad was recognized for his leadership and named Bay Area CFO of the Year by San Francisco Business Times. Brad holds a Bachelor of Science in business from Biola University and an M.B.A. from San Jose State University.
Oncotype DX My Colon Cancer Coach